We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Semaglutide

News List

Novo Nordisk’s diabetes pill presents the first successful data biospectrumasia
February 27, 2018
The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure mounts in a crowded market targeting the world's 450 million diabetics.
Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; prnasia
February 02, 2018
The Lancet Diabetes and Endocrinology has published the results of the SUSTAIN 7 trial
Oral semaglutide shows promise for type 2 diabetes europeanpharmaceuticalreview
October 18, 2017
Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes…
Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial pharmatimes
August 18, 2017
Novo Nordisk’s once-weekly diabetes drug semaglutide has beaten Eli Lilly’s once-weekly therapy dulaglutide on reducing blood sugar and weight in patients taking part in a late-stage trial.

Previous page 1 2 3 4 Next page